Goldman Sachs
DWTX

Goldman Sachs’s Dogwood Therapeutics DWTX Stock Holding History

Goldman Sachs’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8K Buy
+14,598
New +$43K ﹤0.01% 6334

Other funds holding DWTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's DWTX Position: Q1 2026 in Review

Goldman Sachs opened a new position in Dogwood Therapeutics (DWTX) in Q1 2026: 14,598 shares worth $30.8K. The stake represents ﹤0.01% of the portfolio and ranks #6334 among its holdings.

13 funds tracked by Wall St. Rank hold DWTX as of Q1 2026.

  • Goldman Sachs held 14,598 shares of Dogwood Therapeutics worth $30.8K as of Q1 2026.
  • Dogwood Therapeutics was a new Goldman Sachs position in Q1 2026.
  • Dogwood Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6334 holding.
  • 13 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.